<DOC>
	<DOCNO>NCT00391079</DOCNO>
	<brief_summary>The purpose study find cannabis-based medicine compare dummy medicine ( placebo contain active ingredient ) help central neuropathic pain patient experience result multiple sclerosis . This type pain `` central neuropathic pain '' describe shooting , stab , burn sear like sensation , often bad night .</brief_summary>
	<brief_title>Sativex Versus Placebo When Added Existing Treatment Central Neuropathic Pain MS</brief_title>
	<detailed_description>GW show phase II III study Sativex analgesic property effective relieve neuropathic pain . These study suggest Sativex well tolerate may also improve sleep quality life . GW conduct study demonstrate effect .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<criteria>Any disease subtype MS least two year duration Central neuropathic pain ( CNP ) least three month expect remain stable study duration Moderate CNP define NRS pain score baseline sum least 24 Subject establish previously try failed analgesic therapy CNP If receive disease modify medication , stable dose 3 month maintain study duration Subjects whose identify pain likely nociceptive , musculoskeletal ( include spasm ) peripheral neuropathic psychogenic origin , due trigeminal neuralgia . Other non central neuropathic pain severity likely interfere patient assessment CNP medical history suggest subject likely relapse/remit course study history schizophrenia ( include family history ) , psychotic illness , severe personality disorder significant psychiatric disorder depression associate MS know suspected history alcohol abuse , epilepsy recurrent seizure hypersensitivity cannabinoids travel outside country residence plan study significant cardiac , renal hepatic impairment subject current recreational cannabis , medicinal cannabis synthetic cannabinoid base medication within 3 month prior study entry unwilling abstain duration study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Central Neuropathic Pain</keyword>
</DOC>